BetterLife Pharma Inc.
BETRF evidence brief
What we can confirm
- Market Cap:
- $39.3M
What it means
What to watch
Prepared research question
What matters most for BETRF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BETRF
BetterLife Pharma Inc. (BETRF) is a Canadian biotechnology company developing BETR-001, a non-hallucinogenic 5-HT2A neuroplastogen, for migraine and headache disorders, with an IND filing and Phase 1 program underway.
Key risk: Single-asset dependency
Market Cap
$39.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
BetterLife Pharma Inc. (BETRF) is a Canadian biotechnology company developing BETR-001, a non-hallucinogenic 5-HT2A neuroplastogen, for migraine and headache disorders, with an IND filing and Phase 1 program underway.
- Lead asset BETR-001 is a non-hallucinogenic derivative of LSD (2-Br-LSD) targeting migraine and headache disorders [news · published 2026-07-13].
- Closed a CAD $2 million convertible debenture financing in June 2026 to fund IND-enabling work for BETR-001 [news · published 2026-06-22].
- Engaged Nucro-Technics for the final GLP toxicology study required by the FDA for IND and Phase 1 [news · published 2026-07-06].
- Closed a US$100 million public offering of common shares and pre-funded warrants in September 2026 [news · published 2026-09-17].
- Appointed Mahan Chehrenama, DO, as Chief Medical Officer in August 2026 to lead BETR-001 clinical development [news · published 2026-08-19].
What works
- BETR-001 is a non-hallucinogenic, non-scheduled 5-HT2A agonist, differentiating it from other 5-HT2A programs and potentially reducing regulatory and safety hurdles [news · published 2026-07-13].
- The company has secured significant financing (CAD $2M convertible debenture and US$100M public offering) to advance BETR-001 toward an IND filing [news · published 2026-06-22] [news · published 2026-09-17].
- BETR-001 targets a clinically validated, FDA-precedented serotonergic mechanism for migraine and headache disorders, which may de-risk the development pathway [news · published 2026-07-13].
What to weigh
- BETR-001 has not yet filed an IND or initiated Phase 1 trials; all data are preclinical, and clinical efficacy/safety are unproven [news · published 2026-07-06].
- The company has no approved products or revenue from product sales, relying entirely on financing for operations [news · published 2026-06-22].
- The company's pipeline is concentrated on a single asset (BETR-001), creating high dependency on its success [news · published 2026-07-13].
From the filings
Quoted directly from source documents.
BETR-001 is a non-hallucinogenic derivative of LSD
“BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD.”
News · July 6, 2026
BETR-001 is prioritized for migraine and headache disorders
“BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism”
News · July 13, 2026
CAD $2 million convertible debenture financing closed
“BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing”
News · June 22, 2026
US$100 million public offering closed
“BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants”
News · September 17, 2026
Risks & what to watch (3)›
Key risks
- Single-asset dependency — All pipeline focus is on BETR-001; failure would leave the company without a clinical candidate [news · published 2026-07-13].
- Pre-revenue stage — No approved products or product revenue; operations rely entirely on financing [news · published 2026-06-22].
- Clinical development risk — BETR-001 has not yet entered Phase 1; clinical safety and efficacy are unproven [news · published 2026-07-06].
What to watch
- FDA IND filing for BETR-001 and initiation of Phase 1 clinical trials [news · published 2026-07-06].
- Completion of the GLP toxicology study by Nucro-Technics and GMP manufacturing by Syner-G [news · published 2026-07-06] [news · published 2026-06-25].
- Outcome of the Annual General and Special Meeting (AGSM) rescheduled from October 14, 2026 [news · published 2026-09-29].
- Any updates on BETR-001's clinical data or potential expansion into depression and other psychiatric indications [news · published 2026-07-13].
Sources: News · SEC filings · Generated October 3, 2026 · How we verify sources →
Run BetterLife Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BetterLife Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2023Institutional holders
2
Total value held
$192
| Holder | Shares | Value |
|---|---|---|
| bartlett & co. wealth management llc | 4,000 | $192 |
| bartlett & co. llc | 4,000 | $0 |
Frequently asked questions
What is the AI investment thesis for BetterLife Pharma Inc.?
BetterLife Pharma Inc. (BETRF) is a Canadian biotechnology company developing BETR-001, a non-hallucinogenic 5-HT2A neuroplastogen, for migraine and headache disorders, with an IND filing and Phase 1 program underway.
Who is the CEO of BetterLife Pharma Inc.?
Dr. Ahmad Doroudian Ph.D. is the chief executive officer of BetterLife Pharma Inc. (BETRF).
Where is BetterLife Pharma Inc. headquartered?
BetterLife Pharma Inc. (BETRF) is headquartered in Vancouver, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.